Catabasis Pharmaceuticals, Inc. (CATB) Analysts See $-0.23 EPS; EIFFAGE SA ORDINARY SHARES FRANCE (EFGSF) Sellers Increased By 500% Their Shorts

April 17, 2018 - By Dolores Ford

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Logo

Analysts expect Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) to report $-0.23 EPS on May, 10.They anticipate $0.18 EPS change or 43.90% from last quarter’s $-0.41 EPS. After having $-0.24 EPS previously, Catabasis Pharmaceuticals, Inc.’s analysts see -4.17% EPS growth. The stock increased 1.67% or $0.03 during the last trading session, reaching $1.83. About 274,682 shares traded. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has risen 19.23% since April 17, 2017 and is uptrending. It has outperformed by 7.68% the S&P500.

EIFFAGE SA ORDINARY SHARES FRANCE (OTCMKTS:EFGSF) had an increase of 500% in short interest. EFGSF’s SI was 600 shares in April as released by FINRA. Its up 500% from 100 shares previously. It closed at $112.5 lastly. It is down 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Eiffage SA engages in construction, real estate development, civil engineering, metallic construction, road construction, energy, and concessions businesses in France and internationally. The company has market cap of $11.17 billion. This segment operates in the housing, commercial, commercial planning, and hotel sectors. It has a 15.97 P/E ratio. The company's Construction segment is involved in urban development, building design and construction, property development, maintenance, and facility management activities for public and private-sector customers.

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 15 analyst reports since August 17, 2015 according to SRatingsIntel. The company was maintained on Wednesday, June 8 by Wedbush. The rating was maintained by Citigroup with “Neutral” on Thursday, October 5. The firm earned “Buy” rating on Monday, August 17 by Wedbush. The firm has “Buy” rating given on Monday, August 14 by Oppenheimer. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) earned “Outperform” rating by Wedbush on Tuesday, March 20. The rating was maintained by Wedbush with “Buy” on Monday, August 14. The company was maintained on Thursday, October 5 by Cowen & Co. The stock has “Buy” rating by Citigroup on Tuesday, March 22. The rating was upgraded by Citigroup to “Buy” on Monday, November 20. The firm earned “Hold” rating on Thursday, August 10 by Cowen & Co.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $53.14 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.